A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

NCT02737787 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube
Primary Peritoneal Cancer
Recurrent Ovarian Cancer

Interventions

BIOLOGICAL: WT1 Vaccine
DRUG: Nivolumab
BIOLOGICAL: NY-ESO-1 Vaccine

Sponsor

Memorial Sloan Kettering Cancer Center